US 11,833,249 B2
Rapidly disintegrating solid oral dosage forms containing dasatinib
Per Andersson, Uppsala (SE); Thomas Meijer, Segeltorp (SE); and Victor Söderberg, Uppsala (SE)
Assigned to XSPRAY PHARMA AB, Solna (SE)
Filed by XSPRAY PHARMA AB, Solna (SE)
Filed on May 6, 2022, as Appl. No. 17/738,146.
Application 17/738,146 is a continuation of application No. 17/109,344, filed on Dec. 2, 2020, granted, now 11,344,500.
Application 17/109,344 is a continuation of application No. 17/004,153, filed on Aug. 27, 2020, granted, now 10,894,018, issued on Jan. 19, 2021.
Application 17/004,153 is a continuation of application No. 16/700,310, filed on Dec. 2, 2019, granted, now 10,799,459, issued on Oct. 13, 2020.
Claims priority of provisional application 62/909,913, filed on Oct. 3, 2019.
Claims priority of provisional application 62/849,256, filed on May 17, 2019.
Prior Publication US 2022/0257519 A1, Aug. 18, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/20 (2006.01); A61K 9/00 (2006.01); A61K 9/28 (2006.01); A61K 31/506 (2006.01)
CPC A61K 9/2018 (2013.01) [A61K 9/0053 (2013.01); A61K 9/28 (2013.01); A61K 31/506 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A method of treating a proliferative disorder in a patient in need thereof, comprising administering a therapeutically effective amount of a
a tablet for oral administration, comprising
dasatinib 1,2-propanediol solvate, dasatinib (R)-1,2-propanediol solvate, dasatinib (S)-1,2-propanediol solvate, or a combination thereof; and
at least one pharmaceutically acceptable excipient; and
a coating layer;
wherein the tablet releases at least 80% of the dasatinib within 20 minutes when the tablet is tested in a USP Type 2 in 500 mL of 0.01 M hydrochloric acid at about 37° C. and about 75 RPM.